THCA Therapeutics has completed Version 5 of its investor pitch deck, marking another important step in the development of the company’s scientific and investment narrative.

The updated presentation brings together the company’s purpose, the rheumatoid-arthritis development thesis, published preclinical rationale, the THCA PURE™ Oral formulation concept, development planning, intellectual-property strategy and Seed-financing objectives.

Version 5 also introduces a more disciplined approach to scientific communication. Published animal and laboratory findings are clearly distinguished from company-generated evidence, planned studies and unvalidated product hypotheses.

The presentation reflects the current status of THCA Therapeutics as an early-stage, preclinical biotechnology business. THCA PURE™ Oral remains an investigational formulation concept that has not yet been prototyped, clinically validated or approved.

The updated deck is intended to support structured discussions with prospective investors, scientific advisors, pharmaceutical-development partners and other biotechnology stakeholders.